Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Glaukos Corporation stock | $46.27

Learn how to easily invest in Glaukos Corporation stock.

Glaukos Corporation is a medical instruments & supplies business based in the US. Glaukos Corporation shares (GKOS) are listed on the NYSE and all prices are listed in US Dollars. Glaukos Corporation employs 653 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Glaukos Corporation

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – GKOS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Glaukos Corporation stock price (NYSE: GKOS)

Use our graph to track the performance of GKOS stocks over time.

Glaukos Corporation shares at a glance

Information last updated 2021-10-16.
Latest market close$46.27
52-week range$44.37 - $99.00
50-day moving average $51.35
200-day moving average $67.14
Wall St. target price$50.56
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.33

Buy Glaukos Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Glaukos Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Glaukos Corporation price performance over time

Historical closes compared with the close of $46.27 from 2021-10-20

1 week (2021-10-15) 3.24%
1 month (2021-09-22) -9.72%
3 months (2021-07-22) -7.46%
6 months (2021-04-22) -49.57%
1 year (2020-10-21) -17.38%
2 years (2019-10-21) -26.79%
3 years (2018-10-19) 60
5 years (2016-10-21) 32.65%

Is Glaukos Corporation under- or over-valued?

Valuing Glaukos Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Glaukos Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Glaukos Corporation's PEG ratio

Glaukos Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.64. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Glaukos Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Glaukos Corporation financials

Revenue TTM $284.1 million
Gross profit TTM $158 million
Return on assets TTM -2.41%
Return on equity TTM -9.68%
Profit margin -21.24%
Book value $12.58
Market capitalisation $2.1 billion

TTM: trailing 12 months

Shorting Glaukos Corporation shares

There are currently 2.0 million Glaukos Corporation shares held short by investors – that's known as Glaukos Corporation's "short interest". This figure is 14.1% down from 2.3 million last month.

There are a few different ways that this level of interest in shorting Glaukos Corporation shares can be evaluated.

Glaukos Corporation's "short interest ratio" (SIR)

Glaukos Corporation's "short interest ratio" (SIR) is the quantity of Glaukos Corporation shares currently shorted divided by the average quantity of Glaukos Corporation shares traded daily (recently around 608101.54320988). Glaukos Corporation's SIR currently stands at 3.24. In other words for every 100,000 Glaukos Corporation shares traded daily on the market, roughly 3240 shares are currently held short.

However Glaukos Corporation's short interest can also be evaluated against the total number of Glaukos Corporation shares, or, against the total number of tradable Glaukos Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Glaukos Corporation's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Glaukos Corporation shares in existence, roughly 40 shares are currently held short) or 0.044% of the tradable shares (for every 100,000 tradable Glaukos Corporation shares, roughly 44 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Glaukos Corporation.

Find out more about how you can short Glaukos Corporation stock.

Glaukos Corporation share dividends

We're not expecting Glaukos Corporation to pay a dividend over the next 12 months.

Glaukos Corporation share price volatility

Over the last 12 months, Glaukos Corporation's shares have ranged in value from as little as $44.37 up to $99. A popular way to gauge a stock's volatility is its "beta".

GKOS.US volatility(beta: 1.76)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Glaukos Corporation's is 1.7635. This would suggest that Glaukos Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Glaukos Corporation overview

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California. .

Frequently asked questions

What percentage of Glaukos Corporation is owned by insiders or institutions?
Currently 3.843% of Glaukos Corporation shares are held by insiders and 97.191% by institutions.
How many people work for Glaukos Corporation?
Latest data suggests 653 work at Glaukos Corporation.
When does the fiscal year end for Glaukos Corporation?
Glaukos Corporation's fiscal year ends in December.
Where is Glaukos Corporation based?
Glaukos Corporation's address is: 229 Avenida Fabricante, San Clemente, CA, United States, 92672
What is Glaukos Corporation's ISIN number?
Glaukos Corporation's international securities identification number is: US3773221029
What is Glaukos Corporation's CUSIP number?
Glaukos Corporation's Committee on Uniform Securities Identification Procedures number is: 377322102

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site